Navamedic ASA: Enters long term distribution agreement for PrecisionBiotics Zenflore® in the Nordics with Novozymes.
Oslo, April 8, 2021 – Navamedic ASA (OSE: NAVA) enters exclusive long term distribution agreement with Novozymes for PrecisionBiotics Zenflore® in the Nordics. Through this agreement Navamedic strengthens its position within consumer healthcare and clinically proven probiotics for specific disease areas.“We are proud to announce the agreement with Novozymes which expands our product portfolio within probiotics for specific disease areas in the Nordics. The agreement is an extension of the great collaboration between our two companies for PrecisionBiotics Alflorex®, which we launched in 2019,